Ozempic maker Novo Nordisk sues US rival over ‘materially misleading’ ads
Summary
Novo Nordisk is suing the US company Eli Lilly for running misleading ads about their weight-loss and diabetes drugs. Novo Nordisk says Eli Lilly used old studies and left out important information to make their products look better than Novo Nordisk’s.Key Facts
- Novo Nordisk makes the drug Ozempic, which contains semaglutide.
- Eli Lilly makes competing drugs Zepbound and Mounjaro, which contain tirzepatide.
- Novo Nordisk claims Eli Lilly’s ads use outdated studies and hide key details.
- The lawsuit focuses on ads shown during global sports events and on social media.
- Eli Lilly says their ads are based on a direct clinical trial called Surmount-5.
- Both companies’ drugs mimic a natural hormone called GLP-1 that helps with weight loss and diabetes.
- Novo Nordisk wants advertising to be truthful and based on the latest scientific evidence.
- Eli Lilly wants to continue sharing their trial results and stands by their advertising.
Read the Full Article
This is a fact-based summary from The Actual News. Click below to read the complete story directly from the original source.
